Fig. 5

CD200 ameliorates CSDS-induced microglia hyperactivation and hippocampal neuroinflammation. A Experimental timelines for CSDS procedure, CD200Fc administration and behavioral testing. B Representative 3D reconstructions showing the microglial morphology in DG of control and CSDS mice with Iba1 staining (green). Scale bars: 10 μm. C–E Volume of microglia (C), length of branches (D), the number of intersections (E) in the control and CSDS group after CD200Fc administration (n = 9 sections/group from 3 mice, one-way ANOVA with Fisher’s LSD test). F Representative immunostaining for Iba1 (green)/CD68 (red) in DG of control and CSDS mice. Scale bars: 80 μm. G Number of microglia in the control and CSDS group after CD200Fc administration (n = 3 mice per group, two-way ANOVA with Fisher’s LSD test). H Fluorescence intensity of CD68 in microglia in the control and CSDS group after CD200Fc administration (n = 6–8 sections from 3 mice per group, two-way ANOVA with Fisher’s LSD test). I Representative immunostaining for Iba1 (green)/Arg-1 (red) in DG of control and CSDS mice. Scale bars: 80 μm. J Fluorescence intensity of Arg-1 in microglia in the control and CSDS group after CD200Fc administration (n = 12 sections from 3 mice per group, two-way ANOVA with Fisher’s LSD test). Data are expressed as mean ± SEM. *P < 0.05; **P < 0.01. ***P < 0.001. Ctrl, control. See Additional file 1: Table S2 for detailed statistical information